The latest peptide research, lab-quality, and regulatory news — summarized in plain language and linked to primary sources. For informational use only; not medical advice. 21+.
-
Warning Letters Are Not New Rules: FDA Enforcement vs Rulemaking on Peptides
Five FDA warning letters to peptide sellers were posted on 1 September 2026. They apply existing law to five named firms. They did not change the rules for anyone else.
-
Peptide Sports Medicine Reviews: Four 2026 Papers, One Verdict on the Evidence
Four peer-reviewed 2026 reviews assessed BPC-157, TB-500, CJC-1295, MK-677, ipamorelin and GHK-Cu for musculoskeletal use. The most systematic found 67% of the literature is animal research.
-
How Peptides Are Analysed: HPLC, LC–MS/MS and Stability Testing
A 2026 review in Separation Science Plus surveys peptide analysis methods and names LC–MS/MS the gold standard for quantification. How chromatographic purity, mass-spectrometric identity and stability testing answer different questions.
-
Boehringer Ingelheim’s Triple Receptor Agonist BI 3034701 Enters Phase II
Boehringer Ingelheim says its investigational GLP-1/GIP/NPY2 triple receptor agonist BI 3034701 has entered Phase II development for obesity. What the company announced, and what a Phase II start does and does not mean.
-
Pharmacopeias move toward recombinant Factor C for endotoxin testing
USP and the European Pharmacopoeia now formally recognise recombinant Factor C for bacterial endotoxin testing, and why endotoxin is a separate result on a COA.
-
CagriSema is under FDA review, with a decision anticipated by late 2026
Novo Nordisk filed CagriSema with the FDA in December 2025 and says a decision is anticipated by late 2026. What the REDEFINE trials showed, and what REDEFINE 4 did not.
-
Retatrutide’s Phase 3 diabetes data published in The Lancet and presented at ADA 2026
Retatrutide’s first Phase 3 type 2 diabetes trial, TRANSCEND-T2D-1, was published in The Lancet and presented with TRIUMPH-1 obesity data at ADA 2026.